Logo image of NTLA

INTELLIA THERAPEUTICS INC (NTLA) Stock Fundamental Analysis

NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD

12.17  -0.08 (-0.65%)

After market: 12.0419 -0.13 (-1.05%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NTLA. NTLA was compared to 572 industry peers in the Biotechnology industry. NTLA has a great financial health rating, but its profitability evaluates not so good. NTLA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NTLA had negative earnings in the past year.
In the past year NTLA has reported a negative cash flow from operations.
In the past 5 years NTLA always reported negative net income.
In the past 5 years NTLA always reported negative operating cash flow.
NTLA Yearly Net Income VS EBIT VS OCF VS FCFNTLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M -400M -500M

1.2 Ratios

NTLA has a worse Return On Assets (-74.26%) than 67.32% of its industry peers.
NTLA has a Return On Equity (-90.52%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -74.26%
ROE -90.52%
ROIC N/A
ROA(3y)-29.63%
ROA(5y)-27.7%
ROE(3y)-36.65%
ROE(5y)-34.46%
ROIC(3y)N/A
ROIC(5y)N/A
NTLA Yearly ROA, ROE, ROICNTLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10 -20 -30 -40

1.3 Margins

NTLA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTLA Yearly Profit, Operating, Gross MarginsNTLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

More info and screens

7

2. Health

2.1 Basic Checks

NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
NTLA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NTLA has more shares outstanding
NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NTLA Yearly Shares OutstandingNTLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
NTLA Yearly Total Debt VS Total AssetsNTLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

NTLA has an Altman-Z score of -0.79. This is a bad value and indicates that NTLA is not financially healthy and even has some risk of bankruptcy.
NTLA has a Altman-Z score (-0.79) which is comparable to the rest of the industry.
NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.79
ROIC/WACCN/A
WACC9.44%
NTLA Yearly LT Debt VS Equity VS FCFNTLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

A Current Ratio of 6.73 indicates that NTLA has no problem at all paying its short term obligations.
NTLA's Current ratio of 6.73 is fine compared to the rest of the industry. NTLA outperforms 65.72% of its industry peers.
A Quick Ratio of 6.73 indicates that NTLA has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.73, NTLA is doing good in the industry, outperforming 65.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.73
Quick Ratio 6.73
NTLA Yearly Current Assets VS Current LiabilitesNTLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

6

3. Growth

3.1 Past

The earnings per share for NTLA have decreased by -1.68% in the last year.
Looking at the last year, NTLA shows a very strong growth in Revenue. The Revenue has grown by 57.03%.
NTLA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.58% yearly.
EPS 1Y (TTM)-1.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.9%
Revenue 1Y (TTM)57.03%
Revenue growth 3Y-14.48%
Revenue growth 5Y3.58%
Sales Q2Q%-24.02%

3.2 Future

NTLA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.07% yearly.
The Revenue is expected to grow by 86.23% on average over the next years. This is a very strong growth
EPS Next Y-0.26%
EPS Next 2Y1.76%
EPS Next 3Y0.61%
EPS Next 5Y20.07%
Revenue Next Year3.95%
Revenue Next 2Y1.48%
Revenue Next 3Y-6.65%
Revenue Next 5Y86.23%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NTLA Yearly Revenue VS EstimatesNTLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
NTLA Yearly EPS VS EstimatesNTLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10 -10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NTLA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NTLA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTLA Price Earnings VS Forward Price EarningsNTLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTLA Per share dataNTLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.76%
EPS Next 3Y0.61%

More info and screens

0

5. Dividend

5.1 Amount

NTLA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTELLIA THERAPEUTICS INC

NASDAQ:NTLA (2/21/2025, 8:00:01 PM)

After market: 12.0419 -0.13 (-1.05%)

12.17

-0.08 (-0.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)02-27 2025-02-27/amc
Inst Owners92.53%
Inst Owner Change-73.25%
Ins Owners1.23%
Ins Owner Change-0.34%
Market Cap1.24B
Analysts80.61
Price Target49.52 (306.9%)
Short Float %24.88%
Short Ratio8.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.91%
Min EPS beat(2)-20.94%
Max EPS beat(2)5.12%
EPS beat(4)3
Avg EPS beat(4)1.45%
Min EPS beat(4)-20.94%
Max EPS beat(4)20.41%
EPS beat(8)6
Avg EPS beat(8)3.89%
EPS beat(12)7
Avg EPS beat(12)-5.81%
EPS beat(16)7
Avg EPS beat(16)-9.62%
Revenue beat(2)1
Avg Revenue beat(2)-25.35%
Min Revenue beat(2)-64.41%
Max Revenue beat(2)13.7%
Revenue beat(4)2
Avg Revenue beat(4)-4.69%
Min Revenue beat(4)-114.65%
Max Revenue beat(4)146.59%
Revenue beat(8)5
Avg Revenue beat(8)0.99%
Revenue beat(12)9
Avg Revenue beat(12)12.53%
Revenue beat(16)9
Avg Revenue beat(16)-0.26%
PT rev (1m)-17.95%
PT rev (3m)-17.72%
EPS NQ rev (1m)1.66%
EPS NQ rev (3m)1.66%
EPS NY rev (1m)-0.07%
EPS NY rev (3m)1.83%
Revenue NQ rev (1m)-5.98%
Revenue NQ rev (3m)-5.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.03%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.25
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-5.44
EYN/A
EPS(NY)-5.22
Fwd EYN/A
FCF(TTM)-3.56
FCFYN/A
OCF(TTM)-3.5
OCFYN/A
SpS0.8
BVpS9.45
TBVpS9.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -74.26%
ROE -90.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.63%
ROA(5y)-27.7%
ROE(3y)-36.65%
ROE(5y)-34.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.97%
Cap/Sales 7.77%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.73
Quick Ratio 6.73
Altman-Z -0.79
F-Score3
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)173.38%
Cap/Depr(5y)139.7%
Cap/Sales(3y)34.39%
Cap/Sales(5y)25.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.68%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.9%
EPS Next Y-0.26%
EPS Next 2Y1.76%
EPS Next 3Y0.61%
EPS Next 5Y20.07%
Revenue 1Y (TTM)57.03%
Revenue growth 3Y-14.48%
Revenue growth 5Y3.58%
Sales Q2Q%-24.02%
Revenue Next Year3.95%
Revenue Next 2Y1.48%
Revenue Next 3Y-6.65%
Revenue Next 5Y86.23%
EBIT growth 1Y-88.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.42%
EBIT Next 3Y-7.29%
EBIT Next 5Y26.74%
FCF growth 1Y-16.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.68%
OCF growth 3YN/A
OCF growth 5YN/A